Cas:176896-73-4 methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoate manufacturer & supplier

Chemical Name:methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoate

CAS.NO:176896-73-4

Synonyms:N-tert-butyloxycarbonyl 2-naphthylalanine methyl ester;Boc-2-Nal-OMe

Molecular Formula:C₁₉H₂₃NO₄

Molecular Weight:329.39000

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:68.12000

Exact Mass:329.16300

LogP:3.65300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-tert-butyloxycarbonyl 2-naphthylalanine methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Boc-2-Nal-OMe physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-tert-butyloxycarbonyl 2-naphthylalanine methyl ester Use and application,N-tert-butyloxycarbonyl 2-naphthylalanine methyl ester technical grade,usp/ep/jp grade.

Related News: Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. 2-Undecanamine, 6,10-dimethyl- manufacturers So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. 3-(2,6-dimethylphenyl)-1-(2-methylsulfanylphenyl)propan-1-one suppliers This further investment in enhanced facilities and continuous staff development provides the increased range of testing services required by the international biopharmaceutical industry. N-[3-(4-nitrophenyl)-2-propenyl]-N’-[bis(4-fluorophenyl)methyl]piperazine vendor & factory EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. ,Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.